Log In
Print
BCIQ
Print
Print this Print this
 

Anti-vWF Nanobody, caplacizumab (ALX-0081/ALX-0681)

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionNanobodies targeting von Willebrand factor (vWF)
Molecular Target von Willebrand factor (vWF)
Mechanism of Actionvon Willebrand factor (vWF) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationThrombocytopenia
Indication DetailsTreat thrombotic thrombocytopenic purpura (TTP)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today